Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Scot Ebbinghaus"'
Autor:
Jin Zhang, Jeffrey S. Weber, James R. Anderson, Anthony M. Joshua, Adil Daud, Scot Ebbinghaus, Richard F. Kefford, Richard W. Joseph, Amita Patnaik, Peter Hersey, Wen-Jen Hwu, Omid Hamid, Caroline Robert, Tara C. Gangadhar, Antoni Ribas, Scott J. Diede, F. Stephen Hodi, Hassane M. Zarour, Roxana S. Dronca, Jedd D. Wolchok
Publikováno v:
Journal of Clinical Oncology. 36:1668-1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation af
Autor:
Richard S. Finn, H. Y. Lim, Stephen L. Chan, Scot Ebbinghaus, Marcelo Garrido, Jennifer J. Knox, Valeriy Breder, Yee Chao, Abby B. Siegel, Andrew X. Zhu, Philippe Merle, Mohamed Bouattour, Julien Edeline, Erluo Chen, Ann-Lii Cheng, Sadahisa Ogasawara, Baek-Yeol Ryoo, Masatoshi Kudo, Thomas Yau, Bruno Daniele
Publikováno v:
Journal of Clinical Oncology. 37:4004-4004
4004 Background: Pembro received accelerated approval based on results of KEYNOTE-224, a phase 2 trial in pts with advanced HCC in the second line setting. KEYNOTE-240 (NCT02702401) was a randomized, placebo (Pbo) controlled, phase 3 study of Pembro
Autor:
Arthur P. Staddon, Jean-Yves Blay, Yang Song, Thierry Alcindor, Lee D. Cranmer, Frank G. Haluska, Sant P. Chawla, Scot Ebbinghaus, George D. Demetri, Daniel A. Rushing, Nicolas Penel, Isabelle Ray-Coquard, Mohammed M. Milhem, John W. Loewy, Richard F. Riedel, Pierre F. Dodion, Ruey Min Lee, Emmanuelle Bompas, Peter Reichardt, B. Bui-Nguyen, Joseph E. Eid, Axel Le Cesne
Publikováno v:
Journal of Clinical Oncology. 31:2485-2492
Purpose Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of systemic chemotherapy used to treat metastatic sarcomas. This large randomized placeb
Autor:
Roy S. Herbst, Bert L. Lum, Tanyifor M. Tohnya, Avi Ashkenazi, Meredith A. Goldwasser, William Novotny, S. Gail Eckhardt, Scot Ebbinghaus, Adrian M. Jubb, Michael S. Gordon, Razelle Kurzrock, David S. Mendelson, Peter J. O'Dwyer
Publikováno v:
Journal of Clinical Oncology. 28:2839-2846
PurposeApoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (Apo2L/TRAIL)—a member of the tumor necrosis factor cytokine family—induces apoptosis by activating the extrinsic pathway through the proapoptotic death receptors
Autor:
Wayne Nicholls, Julia Glade-Bender, Scot Ebbinghaus, Alberto S. Pappo, Jacek Toporski, Steven G. DuBois, Catherine Vezina, Theodore W. Laetsch, Lynley V. Marshall, Hyoung Jin Kang, Martin Ebinger, Kumudu Pathiraja, Susan L. Cohn, Navin R. Pinto, Elizabeth Fox, Michal Yalon-Oren, Birgit Geoerger, Antonio Sergio Petrilli, Scott J. Diede, Margaret E. Macy
Publikováno v:
Journal of Clinical Oncology. 36:10525-10525
10525Background: In the phase 1 portion of KEYNOTE-051 (NCT02332668), the 2-mg/kg-Q3W dose of pembro was identified as the pediatric recommended phase 2 dose. We provide an update on the safety and...
Autor:
Richard S. Finn, Stephen L. Chan, Stéphane Cattan, Gontran Verset, Daniel H. Palmer, Bruno Daniele, Sadahisa Ogasawara, Jennifer J. Knox, Julien Edeline, Debashis Sarker, Laetitia Fartoux, Junshui Ma, Vittorina Zagonel, Chris Verslype, Abby B. Siegel, Ann-Lii Cheng, Arndt Vogel, Andrew X. Zhu, Masatoshi Kudo, Scot Ebbinghaus
Publikováno v:
Journal of Clinical Oncology. 36:4020-4020
4020Background: Initial results from KEYNOTE-224 (NCT02702414), an open label, phase 2 trial showed that pembro, an anti-PD-1 antibody, was active and safe in pts with advanced HCC previously treat...
Autor:
Debashis Sarker, Junshui Ma, Jennifer J. Knox, Julien Edeline, Masatoshi Kudo, Sadahisa Ogasawara, Richard S. Finn, Stephen L. Chan, Scot Ebbinghaus, Olivier Rosmorduc, Daniel H. Palmer, Andrew X. Zhu, Vittorina Zagonel, Chris Verslype, Bruno Daniele, Gontran Verset, Ann-Lii Cheng, Arndt Vogel, Abby B. Siegel, Stéphane Cattan
Publikováno v:
Journal of Clinical Oncology. 36:209-209
209 Background: Immunotherapy approaches, including immune checkpoint blockade, have shown initial promising results in HCC. Anti PD-1 therapy with pembrolizumab has demonstrated antitumor activity and manageable safety in multiple cancers. KEYNOTE-2
Autor:
Debra A. Patt, Marley Boyd, Jenny Black-Shinn, Kendall Lee Stevinson, Charles Lance Cowey, Frank Xiaoqing Liu, Scot Ebbinghaus
Publikováno v:
Journal of Clinical Oncology. 35:e21015-e21015
e21015 Background: PD-1 monoclonal antibodies are promising immunotherapies approved for treatment of patients (pts) with advanced melanoma. As the first US FDA approved PD-1 antibody, pembrolizumab (pembro) has demonstrated efficacy and safety in cl
Autor:
Scot Ebbinghaus, Alberto S. Pappo, Jacek Toporski, Steven G. DuBois, Susan L. Cohn, Scott J. Diede, Hyoung Jin Kang, Lynley V. Marshall, Margaret E. Macy, Navin R. Pinto, Elizabeth Fox, Birgit Geoerger, Michal Yalon-Oren, Antonio Sergio Petrilli, Catherine Vezina, Theodore W. Laetsch, Kumudu Pathiraja, Rupert Handgretinger, Julia Glade-Bender, Wayne Nicholls
Publikováno v:
Journal of Clinical Oncology. 35:10525-10525
10525 Background: In phase 1 of the KEYNOTE-051 study (NCT02332668), the 2 mg/kg Q3W approved adult dose of pembro was also determined to be the pediatric recommended phase 2 dose. In phase 2, presented herein, we further evaluated this dose in pedia
Autor:
Alberto S. Pappo, Scot Ebbinghaus, Lynley V. Marshall, Julie R. Park, Elizabeth Fox, Karl Heath, Michael Yalon Oren, Birgit Geoerger, Scott J. Diede
Publikováno v:
Journal of Clinical Oncology. 34:TPS10585-TPS10585
TPS10585Background: Pembro, a highly selective humanized monoclonal antibody that directly blocks the interaction between programmed death 1 (PD-1) and its ligands PD-L1 and PD-L2, is indicated for...